Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 15;16(4):e58302.
doi: 10.7759/cureus.58302. eCollection 2024 Apr.

Understanding Antithrombotic Agents for Rehabilitation Therapy: A Comprehensive Narrative Review

Affiliations
Review

Understanding Antithrombotic Agents for Rehabilitation Therapy: A Comprehensive Narrative Review

Shuji Matsumoto et al. Cureus. .

Abstract

In rehabilitation medicine, attention must be paid to the medication. Among them, antithrombotic drugs are used for the initial treatment and secondary prevention of stroke, so as a basic knowledge, the pharmacological actions, characteristics, indications, and precautions for the use of antithrombotic drugs should be known. Antithrombotic agents are divided into antiplatelet agents and anticoagulants, and the appropriate antithrombotic agent is selected according to the main disease or condition. Antiplatelet agents include aspirin, clopidogrel, ticlopidine, prasugrel, ticagrelor, and cilostazol. Each antiplatelet agent has a different mechanism of action, characteristics, and indications, and should be prescribed with due consideration. Anticoagulants include heparin, synthetic Xa inhibitors, direct oral anticoagulants (DOACs), synthetic antithrombin agents, and warfarin. Knowledge of the mechanism of action, characteristics, and indications of each anticoagulant is necessary, as well as monitoring and dose adjustment. With regard to ischemic cerebrovascular disease (ICD) and antithrombotic agents, the first step is to classify cerebral infarction and to determine whether antiplatelet agents or anticoagulants should be used. Bleeding and recurrence prevention are important considerations in the selection of appropriate antithrombotic agents for the pathophysiology of ICD.

Keywords: anticoagulant drugs; antiplatelet agent; antithrombotic agent; direct oral anticoagulant (doac); ischemic cerebrovascular disease; rehabilitation medicine; risk of bleeding; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Mechanisms of platelet activation and mechanisms of action of antiplatelet agents
Figure created by the author 5HT2: 5-hydroxytryptamine 2, ADP: adenosine diphosphate, TXA2: thromboxane A2, PAR-1: protease-activated receptor-1, vWF: von Willebrand factor, GP: glycoprotein, PLC: phospholipase C, DG: I, 2-diacylglycerol, GMP: guanosine monophosphate, AMP: adenosine monophosphate, GC: guanylate cyclase, AC: adenylate cyclase, NO: nitric oxide, PG: prostaglandin, IP receptor: prostacyclin receptor
Figure 2
Figure 2. Action mechanism of warfarin
Figure created by the author PIVKA: protein induced by vitamin K absence or antagonists

Similar articles

References

    1. Assessment of activities and participation of people by rehabilitation-focused clinical registries: a systematic scoping review. Gutierrez-Arias R, Neculhueque-Zapata X, Valenzuela-Suazo R, et al. Eur J Phys Rehabil Med. 2023;59:640–652. - PMC - PubMed
    1. Pathophysiology and treatment of stroke: present status and future perspectives. Kuriakose D, Xiao Z. Int J Mol Sci. 2020;21 - PMC - PubMed
    1. Japan Stroke Society guideline 2021 for the treatment of stroke. Miyamoto S, Ogasawara K, Kuroda S, et al. Int J Stroke. 2022;17:1039–1049. - PMC - PubMed
    1. Our efforts for ideal stroke prevention and treatment in japan. Yamaguchi T. Stroke. 2022;53:1030–1036. - PubMed
    1. Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention. Erbay MI, Pyrpyris N, Susarla S, et al. Expert Opin Drug Saf. 2024;23:149–160. - PubMed

LinkOut - more resources